Sinovac Biotech Ltd
SVA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001084201
No open-market purchases or sales by Sinovac Biotech Ltd insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $224.9M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Sinovac Biotech Ltd changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 30 | 9 | −21 |
| Shares | 11.8M | 9.02M | −2.77M (−23.5%) |
| Value | $44.0M | $380.2M | +$336.3M (+765.1%) |
New holders (0)
Institutions that held Sinovac Biotech Ltd at the end of Q4 2022 but not at the end of Q3 2022.
None.
Sold out (21)
Institutions that held Sinovac Biotech Ltd at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Renaissance Technologies LLC | 2,375,841 | $1.54M |
| State Street Corp | 160,875 | $1.04M |
| Yorktown Management & Research Co Inc | 74,893 | $485.0K |
| Skandinaviska Enskilda Banken AB (publ) | 40,000 | $259.0K |
| Geode Capital Management, LLC | 27,717 | $179.0K |
| Susquehanna International Group, LLP | 16,430 | $106.0K |
| Northern Trust Corp | 13,787 | $55.0K |
| Morgan Stanley | 4,141 | $27.0K |
| JPMorgan Chase & Co | 3,000 | $19.0K |
| UBS Group AG | 2,095 | $14.0K |
| Wells Fargo & Company | 1,687 | $11.0K |
| Credit Suisse AG | 656 | $1.00K |
| Northwestern Mutual Wealth Management Co | 102 | $1.00K |
| US Bancorp | 127 | $0 |
| Bank of America Corp | 427 | $0 |
| Clearstead Advisors, LLC | 500 | $0 |
| Royal Bank of Canada | 516 | $0 |
| Spark Investment Management LLC | 29,100 | $0 |
| Eqis Capital Management, Inc. | 17,029 | $0 |
| Advisor Group Holdings, Inc. | 1,364 | $0 |
| Group One Trading, L.P. | 412 | – |